Tumor Stroma Interactions
The Tumor Stroma Interactions group studies the mechanisms leading to leukemia progression.
Projects & clinical trials
Some of the group’s research projects include:
- Exosomes in B-cell malignancies – to identify potential biomarkers in exosomes derived from murine preclinical models and cells of patients affected by hematologic malignancies and to test their influence on cells from the microenvironment.
- Tumor immunology – to identify new cellular populations which could be used as biomarkers for the response to treatment and potential new therapeutic targets.
- New therapeutic targets in CLL – to investigate the therapeutic efficacy and mode of action of new molecules inhibiting translation machinery and prohibitins in chronic lymphocytic leukemia (CLL), both in patient cells and in a murine model.
Featured team members
-
Titiksha
Basu Postdoctoral Fellow -
Coralie
Borne Postdoctoral Fellow -
Iria
Fernandez Botana -
Maxmilan
Jeyakumar Postdoctoral Fellow -
Anne
Largeot Scientist -
Pablo Elias
Morande Postdoctoral Fellow -
Etienne
Moussay Group Leader -
Jérôme
Paggetti Group Leader
Scientific publications
-
Extracellular vesicle secretion by leukemia cells in vivo promotes CLL progression by hampering antitumor T-cell responses – 15/09/2022
-
Single-Cell Omics Analyses Identify the TIM-3 Ligand Galectin-9 As Novel Immunotherapy Target for Chronic Lymphocytic Leukemia – 15/11/2022
-
Small extracellular vesicles – 27/09/2022
-
The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model – 06/09/2022
-
Targeting translation by disrupting the newly identified prohibitin-eif4f complex as a novel therapeutic strategy in chronic lymphocytic leukemia – 01/06/2022
-
Editor’s Note – 15/04/2022
-
PRMT2 : un facteur épigénétique anti-inflammatoire impliqué dans l’agressivité des leucémies aiguës myéloblastiques – 01/03/2022
-
A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia – 28/02/2022
-
Editorial – 03/02/2022
-
Editorial – 17/01/2022
-
Editorial – 15/12/2021
-
Impact of small extracellular vesicles on anti-tumor immunity in chronic lymphocytic leukemia in vivo – 17/11/2021
-
The tumor microenvironment-dependent transcription factors ahr and hif-1α are dispensable for leukemogenesis in the eµ-tcl1 mouse model of chronic lymphocytic leukemia – 08/09/2021
-
In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia – 26/07/2021
-
AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms – 22/07/2021
-
Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy – 01/01/2021
-
Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia – 21/06/2021
-
Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome In Vitro by Pharmacological Inhibition of Cdc42-Induced Actin Cytoskeleton Remodeling – 24/05/2021
-
Method for the Analysis of the Tumor Microenvironment by Mass Cytometry – 20/10/2020
-
Diagnostic and Therapeutic Potential of Extracellular Vesicles in B-Cell Malignancies – 29/09/2020
Related News
-
Fighting cancer in Luxembourg: Legs Kanning Prize 2022
-
Master hijackers: uncovering how leukaemia disarms the body’s defences
-
Gathering Global Insights on Leukaemia Research
-
Pelican grant: Three LIH students awarded
-
FNR Awards 2021: LIH researchers shine at centre-stage
-
LIH leukaemia project to be supported by “Marie Sklodowska-Curie Individual Fellowships”
